Voydeya Interactions
There are 212 drugs known to interact with Voydeya (danicopan), along with 2 disease interactions. Of the total drug interactions, 41 are major, 158 are moderate, and 13 are minor.
- View Voydeya disease interactions (2)
Medications known to interact with Voydeya
Note: Showing generic names only.
A
- abrocitinib
- adalimumab
- afatinib
- alefacept
- alemtuzumab
- aliskiren
- allogeneic processed thymus tissue
- alpelisib
- alvimopan
- anakinra
- apixaban
- armodafinil
- artesunate
- ashwaganda
- asparaginase erwinia chrysanthemi
- asparaginase escherichia coli
- atezolizumab
- atorvastatin
- avelumab
- azathioprine
B
- baricitinib
- bcg
- bedaquiline
- belinostat
- berotralstat
- betrixaban
- bifidobacterium infantis
- black cohosh
- bosutinib
- brentuximab
- brewer's yeast
C
- cabazitaxel
- calaspargase pegol
- canakinumab
- cannabidiol
- cat's claw
- cemiplimab
- ceritinib
- certolizumab
- cladribine
- clofarabine
- cobimetinib
- colchicine
- cosibelimab
- cyclosporine
D
- dabigatran
- daclatasvir
- daclizumab
- darolutamide
- daunorubicin
- daunorubicin liposomal
- delafloxacin
- denosumab
- deucravacitinib
- dextromethorphan
- digoxin
- dimethyl fumarate
- diroximel fumarate
- docetaxel
- dostarlimab
- doxorubicin
- doxorubicin liposomal
- durvalumab
E
- echinacea
- edoxaban
- efalizumab
- efavirenz
- elagolix
- elderberry
- eliglustat
- eltrombopag
- empagliflozin
- enfortumab vedotin
- epirubicin
- erlotinib
- erythromycin
- etanercept
- etoposide
- etranacogene dezaparvovec
- etrasimod
- everolimus
F
G
I
- idarubicin
- idelalisib
- imatinib
- indacaterol
- infliximab
- interferon beta-1a
- interferon beta-1b
- ipilimumab
- irinotecan
- irinotecan liposomal
- isoniazid
K
L
- lactobacillus acidophilus
- lactobacillus reuteri
- lactobacillus rhamnosus
- lactobacillus rhamnosus gg
- lapatinib
- larotrectinib
- leflunomide
- lemborexant
- letermovir
- levoketoconazole
- linagliptin
- lomitapide
- loncastuximab tesirine
- loperamide
- lurasidone
- lusutrombopag
M
- maraviroc
- mavorixafor
- methadone
- methotrexate
- mibefradil
- mipomersen
- mitoxantrone
- monomethyl fumarate
- morphine
N
- nadofaragene firadenovec
- naldemedine
- naloxegol
- naltrexone
- natalizumab
- nilotinib
- nintedanib
- niraparib
- nivolumab
O
P
- paclitaxel
- pazopanib
- pegaspargase
- peginterferon beta-1a
- pembrolizumab
- pexidartinib
- ponesimod
- posaconazole
- pralsetinib
- pretomanid
Q
R
- ranolazine
- relugolix
- remdesivir
- repotrectinib
- retifanlimab
- rifampin
- rifaximin
- rilonacept
- rimegepant
- riociguat
- ripretinib
- ritlecitinib
- ritonavir
- rivaroxaban
- roflumilast
- romidepsin
- rosuvastatin
- rucaparib
S
- saccharomyces boulardii lyo
- seladelpar
- selexipag
- silodosin
- siponimod
- sipuleucel-T
- sirolimus
- sirolimus protein-bound
- streptococcus salivarius
- sulfasalazine
T
- tacrolimus
- talazoparib
- talimogene laherparepvec
- tenofovir alafenamide
- tenofovir disoproxil
- tepotinib
- terfenadine
- teriflunomide
- thioguanine
- ticagrelor
- tipranavir
- tislelizumab
- tofacitinib
- tolvaptan
- topotecan
- toripalimab
- trabectedin
- tremelimumab
U
V
- valoctocogene roxaparvovec
- vemurafenib
- venetoclax
- vinblastine
- vincristine
- vincristine liposome
- vinorelbine
- vitamin e
- voclosporin
Z
Voydeya disease interactions
There are 2 disease interactions with Voydeya (danicopan) which include:
More about Voydeya (danicopan)
- Voydeya consumer information
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.